Research Article
Obesity and the Odds of Weight Gain following Androgen Deprivation Therapy for Prostate Cancer
Table 1
Distribution and comparison of clinical factors at randomization of the study cohort stratified by randomized treatment arm.
| | Clinical factor | Treatment with RT
| Treatment with RT and AST
| value |
| | Median BMI (IQR) | 27.44 kg/m2
(25.58, 30.23) | 27.35 kg/m2
(24.68, 30.99) | 0.73 | | Median PSA (IQR) | 11.54 ng/mL
(7.70, 16.40) | 10.85 ng/mL
(7.50, 15.51) | 0.38 | | Median Age (IQR) | 73.36
(70.82, 76.15) | 72.12
(69.07, 74.71) | 0.11 | | T1 | 37 (44%) | 46 (53%) | 0.19 | | T2 | 48 (56%) | 40 (47%) | | Gleason score 6 or less | 26 (31%) | 25 (29%) | 0.92 | | 7 | 45 (53%) | 49 (57%) | | 8 to 10 | 14 (16%) | 12 (14%) | | No or minimal cm | 65 (76%) | 65 (76%) | 0.89 | | Moderate to severe cm | 20 (24%) | 21 (24%) |
|
|
RT indicates radiotherapy; ADT: androgen deprivation therapy; BMI: body mass index; IQR: interquartile range; PSA: prostate-specific antigen; cm: comorbidity.
|
